PMID- 30363717
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201001
IS  - 2330-1619 (Electronic)
IS  - 2330-1619 (Linking)
VI  - 1
IP  - 3
DP  - 2014 Sep
TI  - Famotidine, a Histamine H(2) Receptor Antagonist, Does Not Reduce 
      Levodopa-Induced Dyskinesia in Parkinson's Disease: A Proof-of-Concept Study.
PG  - 219-224
LID - 10.1002/mdc3.12061 [doi]
AB  - The neural mechanisms underlying levodopa-induced dyskinesia (LID) in Parkinson's 
      disease (PD) may involve histamine (H(2)) receptors on striatopallidal pathways. 
      We recently demonstrated that the clinically available oral histamine H(2) 
      receptor antagonist (H(2) RA), famotidine, can reduce l-dopa-induced chorea in 
      MPTP-lesioned macaques. We hypothesized that famotidine may be useful in the 
      treatment of LID in PD patients. We performed a proof-of-concept, double-blind, 
      randomized, multiple cross-over (4x) trial. Seven PD subjects with bothersome 
      dyskinesia were randomized to oral famotidine 80, 120, and 160 mg/day and 
      placebo. Each subject was randomized to receive each of the four treatment phases 
      for 14 days followed by a 7-day wash-out period between each treatment phase. The 
      primary outcome measure was change in the Unified Dyskinesia Rating Scale 
      (UDysRS; part III) between placebo and famotidine. Secondary outcomes were UDysRS 
      (parts I and II), Global Impression of Change, Lang-Fahn Activities of Daily 
      Living Dyskinesia Scale, Unified Parkinson's Disease Rating part III, and adverse 
      events (AEs). Outcomes were evaluated pre- and post-treatment per dose and 
      analyzed using a mixed-effects linear model. There was no significant effect of 
      famotidine treatment on any of the primary or secondary outcome measures compared 
      to placebo (each dose and all doses combined). There were no significant AEs. 
      Even though the sample size of the current study is limited, famotidine seems to 
      be safe in patients with PD and LID, but showed no potential as an antidyskinetic 
      agent.
FAU - Mestre, Tiago A
AU  - Mestre TA
AD  - Division of Neurology The Parkinson's Disease and Movement Disorder Center The 
      Ottawa Hospital Ottawa Ontario Canada.
FAU - Shah, Binit B
AU  - Shah BB
AD  - Department of Neurology University of Virginia Health Sciences Center McKim Hall 
      Charlottesville Virginia USA.
FAU - Connolly, Barbara S
AU  - Connolly BS
AD  - Division of Neurology Department of Medicine McMaster University, Hamilton Health 
      Sciences Hamilton Ontario Canada.
FAU - de Aquino, Camila
AU  - de Aquino C
AUID- ORCID: 0000-0003-1643-9117
AD  - Division of Neurology Movement Disorders Center and Edmond J. Safra Program in 
      Parkinson's Disease, Toronto Western Hospital, University Health Network, 
      University of Toronto Toronto Canada.
FAU - Al Dhakeel, Amaal
AU  - Al Dhakeel A
AD  - Division of Neurology Movement Disorders Center and Edmond J. Safra Program in 
      Parkinson's Disease, Toronto Western Hospital, University Health Network, 
      University of Toronto Toronto Canada.
FAU - Walsh, Richard
AU  - Walsh R
AD  - Movement Disorders Unit Tallaght Hospital and Trinity College Dublin Dublin 
      Ireland.
FAU - Ghate, Taneera
AU  - Ghate T
AD  - Division of Neurology Movement Disorders Center and Edmond J. Safra Program in 
      Parkinson's Disease, Toronto Western Hospital, University Health Network, 
      University of Toronto Toronto Canada.
FAU - Lui, Jane P
AU  - Lui JP
AD  - Department of Pharmacy Toronto Western Hospital Toronto Ontario Canada.
FAU - Fox, Susan H
AU  - Fox SH
AD  - Division of Neurology Movement Disorders Center and Edmond J. Safra Program in 
      Parkinson's Disease, Toronto Western Hospital, University Health Network, 
      University of Toronto Toronto Canada.
LA  - eng
PT  - Journal Article
DEP - 20140626
PL  - United States
TA  - Mov Disord Clin Pract
JT  - Movement disorders clinical practice
JID - 101630279
PMC - PMC6182979
OTO - NOTNLM
OT  - H2 antagonist
OT  - Parkinson's disease
OT  - dyskinesia
OT  - famotidine
OT  - histamine
EDAT- 2014/06/26 00:00
MHDA- 2014/06/26 00:01
PMCR- 2015/06/26
CRDT- 2018/10/27 06:00
PHST- 2014/04/14 00:00 [received]
PHST- 2014/05/21 00:00 [revised]
PHST- 2014/05/26 00:00 [accepted]
PHST- 2018/10/27 06:00 [entrez]
PHST- 2014/06/26 00:00 [pubmed]
PHST- 2014/06/26 00:01 [medline]
PHST- 2015/06/26 00:00 [pmc-release]
AID - MDC312061 [pii]
AID - 10.1002/mdc3.12061 [doi]
PST - epublish
SO  - Mov Disord Clin Pract. 2014 Jun 26;1(3):219-224. doi: 10.1002/mdc3.12061. 
      eCollection 2014 Sep.